GlassScriptPhysician profile
Collette O Brown
NPI 1932203239
$5,040.89
in general payments reported to CMS, 2019-2025
23 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $1,598 · 2023: $1,455 · 2024: $531 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847 · Travel and Lodging: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.52 |
| Travel and Lodging | $288.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,376.69 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $370.45 | 2023-2025 | Minimed 780g |
| Otsuka America Pharmaceutical, INC. | $216.30 | 2022 | |
| Solventum Corporation | $167.65 | 2025 | Prevena |
| Genentech USA, INC. | $149.50 | 2025 | Xolair |
| Idorsia Pharmaceuticals US INC | $146.58 | 2023 | Quviviq |
| Abbvie INC. | $145.06 | 2021-2024 | |
| Coloplast Corp | $134.45 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $125.38 | 2025 | Opsumit, Uptravi |
| Neurocrine Biosciences, INC. | $125.00 | 2023 | Ingrezza |
| Genzyme Corporation | $125.00 | 2023 | |
| Ucb, INC. | $125.00 | 2025 | Nayzilam |
| Viiv Healthcare Company | $125.00 | 2024 | Dovato |
| Takeda Pharmaceuticals U.S.A., INC. | $123.93 | 2025 | Entyvio |
| Sage Therapeutics, LLC | $121.97 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $96.47 | 2023 | |
| Sumitomo Pharma America, INC. | $90.45 | 2023 | Gemtesa |
| Kerecis Limited | $71.14 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Axonics, INC. | $61.54 | 2024 | Bulkamid |
| W. L. Gore & Associates, INC. | $51.67 | 2023 | Gore Synecor Biomaterial |
| Davol INC. | $39.81 | 2021 | |
| Sandoz INC. | $26.75 | 2024 | Hyrimoz |
| Kci USA, INC. | $25.10 | 2023 | Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collette Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.